Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more
Xenon Pharmaceuticals Inc (XENE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.140x
Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) has a cash flow conversion efficiency ratio of -0.140x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.48 Million) by net assets ($581.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xenon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Xenon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Xenon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenon Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enagás S.A
PINK:ENGGF
|
0.006x |
|
Cencosud
SN:CENCOSUD
|
0.007x |
|
Bellway p.l.c
F:41B
|
0.010x |
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
0.001x |
|
La Francaise Des Jeux Sa
PA:FDJ
|
0.169x |
|
Fuchs Petrolub SE Preference Shares
XETRA:FPE3
|
0.063x |
|
Yapi ve Kredi Bankasi AS
IS:YKBNK
|
-0.472x |
|
Sichuan Huafeng Technology Co. Ltd. A
SHG:688629
|
N/A |
Annual Cash Flow Conversion Efficiency for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Xenon Pharmaceuticals Inc from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $581.76 Million | $-279.12 Million | -0.480x | -99.68% |
| 2024-12-31 | $754.90 Million | $-181.39 Million | -0.240x | -53.42% |
| 2023-12-31 | $927.92 Million | $-145.33 Million | -0.157x | -14.80% |
| 2022-12-31 | $721.50 Million | $-98.43 Million | -0.136x | -7.97% |
| 2021-12-31 | $550.03 Million | $-69.50 Million | -0.126x | +55.01% |
| 2020-12-31 | $171.35 Million | $-48.12 Million | -0.281x | -457.67% |
| 2019-12-31 | $91.98 Million | $-4.63 Million | -0.050x | +85.02% |
| 2018-12-31 | $103.30 Million | $-34.72 Million | -0.336x | +57.95% |
| 2017-12-31 | $35.93 Million | $-28.73 Million | -0.799x | -161.07% |
| 2016-12-31 | $63.90 Million | $-19.57 Million | -0.306x | -3.24% |
| 2015-12-31 | $61.03 Million | $-18.10 Million | -0.297x | -8215.27% |
| 2014-12-31 | $72.78 Million | $266.00K | 0.004x | +102.65% |
| 2013-12-31 | $24.12 Million | $-3.32 Million | -0.138x | -103.82% |
| 2012-12-31 | $12.62 Million | $45.57 Million | 3.610x | -- |